Australian Research Council (ARC) Centre of Excellence for Nanoscale BioPhotonics (CNBP), Adelaide, South Australia, 5000, Australia.
University of Adelaide, Robinson Research Institute, School of Biomedicine, Adelaide, South Australia, 5005, Australia.
J Assist Reprod Genet. 2022 Jul;39(7):1503-1513. doi: 10.1007/s10815-022-02485-1. Epub 2022 May 12.
Intracytoplasmic sperm injection (ICSI) addresses male sub-fertility by injecting a spermatozoon into the oocyte. This challenging procedure requires the use of dual micromanipulators, with success influenced by inter-operator expertise. We hypothesized that minimizing oocyte handling during ICSI will simplify the procedure. To address this, we designed and fabricated a micrometer scale device that houses the oocyte and requires only one micromanipulator for microinjection.
The device consisted of 2 components, each of sub-cubic millimeter volume: a Pod and a Garage. These were fabricated using 2-photon polymerization. Toxicity was evaluated by culturing single-mouse presumptive zygotes (PZs) to the blastocyst stage within a Pod, with several Pods (and embryos) docked in a Garage. The development was compared to standard culture. The level of DNA damage/repair in resultant blastocysts was quantified (γH2A.X immunohistochemistry). To demonstrate the capability to carry out ICSI within the device, PZs were microinjected with 4-μm fluorescent microspheres and cultured to the blastocyst stage. Finally, the device was assessed for oocyte traceability and high-throughput microinjection capabilities and compared to standard microinjection practice using key parameters (pipette setup, holding then injecting oocytes).
Compared to standard culture, embryo culture within Pods and a Garage showed no differences in development to the blastocyst stage or levels of DNA damage in resultant blastocysts. Furthermore, microinjection within our device removes the need for a holding pipette, improves traceability, and facilitates high-throughput microinjection.
This novel device could improve embryo production following ICSI by simplifying the procedure and thus decreasing inter-operator variability.
胞浆内单精子注射(ICSI)通过将精子注射到卵母细胞中来解决男性不育问题。这项具有挑战性的操作需要使用双微操作器,操作的成功与否受操作人员专业知识的影响。我们假设在 ICSI 过程中尽量减少卵母细胞的处理将简化操作程序。为了解决这个问题,我们设计并制造了一种微米级的设备,该设备容纳卵母细胞,只需要一个微操作器进行微注射。
该设备由两个组件组成,每个组件的体积都小于立方毫米:一个 Pod 和一个 Garage。它们是使用双光子聚合制造的。通过在 Pod 内培养单个小鼠预期受精卵(PZ)到囊胚阶段来评估毒性,其中几个 Pod(和胚胎)停靠在 Garage 中。将发育情况与标准培养进行比较。用 γH2A.X 免疫组化定量分析囊胚中的 DNA 损伤/修复水平。为了证明在设备内进行 ICSI 的能力,将 PZ 用 4μm 荧光微球进行微注射,并培养至囊胚阶段。最后,评估设备的卵母细胞可追溯性和高通量微注射能力,并使用关键参数(移液器设置、持卵和注射卵)与标准微注射实践进行比较。
与标准培养相比,Pod 和 Garage 内胚胎培养到囊胚阶段的发育或囊胚中 DNA 损伤水平没有差异。此外,我们的设备内的微注射不需要持卵管,提高了可追溯性,并便于高通量微注射。
通过简化操作程序,减少操作人员之间的差异,这种新设备可以提高 ICSI 后的胚胎生产效率。